Stock AnalizAlbemarle Corp. ALB
Major Chemicals · data as of November 13, 2026
Albemarle Corp. (ALB) is a industrial company listed in the US with a market value of about $11.0B. In the twelve months to September 30, 2026 it had revenue of $6.2B and net income of $515M, a net margin of 8.4%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).
Key numbers: a P/E of 22.6, a price to free cash flow of 7.6, 5-year revenue growth of 10% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 61% below the current price.
Score: 2.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.2B | $5.1B | $5.4B | $9.6B | $7.3B | $3.3B | $3.1B | $3.6B | $3.4B | $3.1B | $2.7B |
| Net income | $515M | -$511M | -$1.2B | $1.6B | $2.7B | $124M | $376M | $533M | $694M | $55M | $644M |
| Free cash flow | $1.4B | $692M | -$993M | -$828M | $646M | -$609M | -$52M | -$132M | -$154M | -$14M | $539M |
| EPS (diluted) | $4.13 | $-5.76 | $-11.20 | $13.36 | $22.84 | $1.06 | $3.52 | $5.02 | $6.34 | $0.49 | $5.68 |
| Net margin | 8.4% | -9.9% | -21.9% | 16.4% | 36.8% | 3.7% | 12.0% | 14.9% | 20.5% | 1.8% | 24.0% |
| ROIC | — | -2.3% | -10.3% | 1.5% | 18.3% | 7.6% | 5.4% | 7.9% | 14.1% | 8.2% | 7.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 21 analysts is $139.35, 49% above the current price; targets range from $83.28 to $211.00; the consensus rating is “Buy”; expected EPS is $10.51 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Albemarle’s P/E ratio?
About 22.6, based on the last twelve months of diluted earnings per share (forward P/E about 13.3).
Is Albemarle stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 61% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Albemarle pay a dividend?
Yes. The dividend yield is about 1.71%, and it has paid dividends for 10 years in our data.
Is Albemarle a good stock to buy?
We do not give buy or sell advice. Albemarle scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.